Kathryn Roberts
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
Year:
2026
Year:
2025
The phase 3 INO-VATE trial demonstrated higher rates of remission, measurable residual disease negativity, and improved overall survival for patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) who received inotuzumab ozogamicin (InO) vs standard-of-care chemotherapy (SC). Here, we examined associations between genomic alterations and the efficacy of InO. Of 326 randomized patients, 91 (InO, n = 43; SC, n = 48) had samples evaluable for genomic analysis. The spectrum of gene fusions and other genomic alterations observed was comparable with prior studies of adult ALL. Responses to InO were observed in all leukemic subtypes, genomic alterations, and risk groups. Significantly higher rates of complete remission (CR)/CR with incomplete count recovery were observed with InO vs SC in patients with BCR::ABL1–like ALL (85.7% [6/7] vs 0% [0/5]; P = .0076), with TP53 alterations (100% [5/5] vs 12.5% [1/8]; P = .0047), and in the high-risk BCR::ABL1– (BCR::ABL1–like, low-hypodiploid, KMT2A-rearranged) group (83.3% [10/12] vs 10.5% [2/19]; P < .0001). This retrospective, exploratory analysis of the INO-VATE trial demonstrated potential for benefit with InO for patients with R/R ALL across leukemic subtypes, including BCR::ABL1–like ALL, and for those bearing diverse genomic alterations. Further confirmation of the efficacy of InO in patients with R/R ALL exhibiting the BCR::ABL1–like subtype or harboring TP53 alterations is warranted. This trial was registered at www.ClinicalTrials.gov as #NCT01564784.
Year:
2024
PURPOSE Acute lymphoblastic leukemia (ALL) can occur across all age groups, with a strikingly higher cure rate in children compared with adults. However, the pharmacological basis of age-related differences in ALL treatment response remains unclear. METHODS Studying 767 children and 309 adults with newly diagnosed B-cell ALL enrolled on frontline trials at St Jude Children's Research Hospital, MD Anderson Cancer Center, the Alliance for Clinical Trials in Oncology, and the ECOG-ACRIN Cancer Research Group, we determined the ex vivo sensitivity of leukemia cells to 21 drugs. Twenty-three ALL molecular subtypes were identified using RNA sequencing. We systematically characterized the associations between drug response and ALL genomics in children, adolescents and young adults, and elderly adults. We evaluated the effect of age-related gene expression signature on ALL treatment outcomes. RESULTS Seven ALL drugs (asparaginase, prednisolone, mercaptopurine, dasatinib, nelarabine, daunorubicin, and inotuzumab ozogamicin) showed differential activity between children and adults, of which six were explained by age-related differences in leukemia molecular subtypes. Adolescents and young adults showed similar patterns of drug resistance as older adults, relative to young children. Mercaptopurine exhibited subtype-independent greater sensitivity in children. Transcriptomic profiling uncovered subclusters within CRLF2 -, DUX4 -, and KMT2A -rearranged ALL that were linked to age and cytotoxic drug resistance. In particular, a subset of children had adult-like ALL on the basis of leukemia gene expression patterns across subtypes, despite their chronological age. Resistant to cytotoxic drugs, children with adult-like ALL exhibited poor prognosis in pediatric ALL trials, even after adjusting for age and minimal residual diseases. CONCLUSION Our results provide pharmacogenomic insights into age-related disparities in ALL cure rates and identify leukemia prognostic features for treatment individualization across age groups.
Year:
2024
Genomic alterations of IKZF1 are common and associated with adverse clinical features in B-ALL. The relationship between the type of IKZF1 alteration, disease subtype and outcome are incompletely understood. Leukemia subtype and genomic alterations were determined using transcriptome and genomic sequencing and SNP microarray in 688 pediatric patients with B-ALL in St. Jude Total Therapy 15 and 16 studies. IKZF1 alterations were identified in 115 (16.7%) patients, most commonly in BCR::ABL1 (78%) and CRLF2- rearranged, BCR::ABL1- like B-ALL (70%). These alterations were associated with 5-year cumulative incidence of relapse (CIR) of 14.8 ± 3.3% compared to 5.0 ± 0.9% for patients without any IKZF1 alteration ( P < 0.0001) . IKZF1 deletions of exon 4-7 ( P = 0.0002), genomic IKZF1 plus with any IKZF1 deletion ( P = 0.006) or with focal IKZF1 deletion ( P = 0.0007), and unfavorable genomic subtypes ( P < 0.005) were independently adversely prognostic factors. Associations of genomic IKZF1 plus and exon 4-7 deletions with adverse outcomes were confirmed in an independent cohort. Genomic IKZF1 plus with any IKZF1 deletion, IKZF1 deletion of exon 4-7, and unfavorable subtype confer increased risk of relapse. The type of IKZF1 alteration, together with the subtype, are informative for risk stratification and predict response in patients with B-ALL.
Year:
2024
Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a poorly understood disease. We studied 200 children with γδ T-ALL from 13 clinical study groups to understand the clinical and genetic features of this disease. We found age and genetic drivers were significantly associated with outcome. γδ T-ALL diagnosed in children under 3 years of age was extremely high-risk and enriched for genetic alterations that result in both LMO2 activation and STAG2 inactivation. Mechanistically, using patient samples and isogenic cell lines, we show that inactivation of STAG2 profoundly perturbs chromatin organization by altering enhancer–promoter looping, resulting in deregulation of gene expression associated with T-cell differentiation. High-throughput drug screening identified a vulnerability in DNA repair pathways arising from STAG2 inactivation, which can be targeted by poly(ADP-ribose) polymerase inhibition. These data provide a diagnostic framework for classification and risk stratification of pediatric γδ T-ALL. Significance: Patients with acute lymphoblastic leukemia expressing the gamma delta T-cell receptor under 3 years old or measurable residual disease ≥1% at end of induction showed dismal outcomes and should be classified as having high-risk disease. The STAG2/LMO2 subtype was enriched in this very young age group. STAG2 inactivation may perturb chromatin conformation and cell differentiation and confer vulnerability to poly(ADP-ribose) polymerase inhibition.
Year:
2024
Inotuzumab ozogamicin (InO) is an antibody-drug conjugate that delivers calicheamicin to CD22-expressing cells. In a retrospective cohort of InO-treated patients with B-cell acute lymphoblastic leukemia, we sought to understand the genomic determinants of the response and resistance to InO. Pre- and post-InO–treated patient samples were analyzed by whole genome, exome, and/or transcriptome sequencing. Acquired CD22 mutations were observed in 11% (3/27) of post-InO-relapsed tumor samples, but not in refractory samples (0/16). There were multiple CD22 mutations per sample and the mechanisms of CD22 escape included epitope loss (protein truncation and destabilization) and epitope alteration. Two CD22 mutant cases were post-InO hyper-mutators resulting from error-prone DNA damage repair (nonhomologous/alternative end-joining repair, or mismatch repair deficiency), suggesting that hypermutation drove escape from CD22-directed therapy. CD22-mutant relapses occurred after InO and subsequent hematopoietic stem cell transplantation (HSCT), suggesting that InO eliminated the predominant clones, leaving subclones with acquired CD22 mutations that conferred resistance to InO and subsequently expanded. Acquired loss-of-function mutations in TP53, ATM, and CDKN2A were observed, consistent with a compromise of the G1/S DNA damage checkpoint as a mechanism for evading InO-induced apoptosis. Genome-wide CRISPR/Cas9 screening of cell lines identified DNTT (terminal deoxynucleotidyl transferase) loss as a marker of InO resistance. In conclusion, genetic alterations modulating CD22 expression and DNA damage response influence InO efficacy. Our findings highlight the importance of defining the basis of CD22 escape and eradication of residual disease before HSCT. The identified mechanisms of escape from CD22-targeted therapy extend beyond antigen loss and provide opportunities to improve therapeutic approaches and overcome resistance. These trials were registered at www.ClinicalTrials.gov as NCT01134575, NCT01371630, and NCT03441061.
Year:
2024
Year:
2023
Collaborators (43)
Shondra Pruett-Miller
Associate Member
St. Jude Children's Research Hospital
Lewis Nasr
The University of Texas MD Anderson Cancer Center
Mariko Eguchi
Profesor
Ehime University Graduate School of Medicine
Chi Kong Li
Professor
The Chinese University of Hong Kong (CUHK)
Martin Schrappe
-
riccardo masetti
Assistant Professor
University of Bologna
Kjeld Schmiegelow
-
Seth Karol
Associate Member, Leukemia & Lymphoma Division
St. Jude Children's Research Hospital
Hanne Vibeke Hansen Marquart
Chief Physician; MD, PhD, Clinical Associate Professor
Copenhagen University Hospital
Allen Eng Juh Yeoh
National University of Singapore (NUS)
Atsushi Manabe
Professor
Hokkaido University
Mignon L. Loh
Professor
University of Washington
Reuven Schore
George Washington University
Gabriele Escherich
-
Marina Konopleva
Professor
Albert Einstein College of Medicine
Valentino Conter
-
Meenakshi Devidas
Member and Director of Global Analytics
St. Jude Children's Research Hospital
Beenu Thakral
Associate Professor
The University of Texas MD Anderson Cancer Center Children's Cancer Hospital
John Choi
The University of Alabama
Franco Locatelli
Full Professor of Pediatrics
Catholic University of the Sacred Heart
Steven Kornblau
Professor
The University of Texas MD Anderson Cancer Center
Junko Takita
教授 / Professor
Kyoto University
Szymon Skoczen
Associated Professor
Uniwersytet Jagiellonski Collegium Medicum
Joseph D. Khoury
University of Nebraska Medical Center
David Teachey
Professor
Children's Hospital of Philadelphia
Daisuke Tomizawa
Head
National Center For Child Health and Development
Cheng Cheng
Professor
St Jude Grade School of Biomedical Sciences
Motohiro Kato
-
Gang Wu
Associate Member
St. Jude Children's Research Hospital
Takao Deguchi
Head of Division
National Center For Child Health and Development
Nicholas J. Short
-
Daniel DeAngelo
Chief of the Division of Leukemia
Dana-Farber Cancer Institute
Ching-Hon Pui
Fahad Nasser Al-Rashid Chair of Leukemia Research
St. Jude Children's Research Hospital
Andrew Moore
Associate Professor
University of Queensland
Ilaria Iacobucci
Principal Scientist
St. Jude Children's Research Hospital
Masatoshi Takagi
Tokyo Medical and Dental University
Jiyang Yu
Interim Chair
St. Jude Children's Research Hospital
Michael Burke
Professor
Medical College of Wisconsin
Zhaohui Gu
Assistant Professor
Beckman Research Institute, City of Hope
Paul G Thomas
Professor
Fred Hutch Cancer Center
Andishe Attarbaschi
Medical University of Vienna
Charles Mullighan
Senior Deputy Director, St. Jude Children's Research Hospital Comprehensive Cancer Center
St. Jude Children's Research Hospital
Rishi Kotecha
Professor
Telethon Kids Institute
Make your next move.
Prepare your application
Review drafts before you send them.